Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Receivables - Net (2016 - 2025)

Integra Lifesciences Holdings' Receivables - Net history spans 17 years, with the latest figure at $278.8 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 2.38% year-over-year to $278.8 million; the TTM value through Dec 2025 reached $278.8 million, up 2.38%, while the annual FY2025 figure was $278.8 million, 2.38% up from the prior year.
  • Receivables - Net for Q4 2025 was $278.8 million at Integra Lifesciences Holdings, up from $262.2 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $284.5 million in Q2 2025 and bottomed at $222.2 million in Q3 2021.
  • The 5-year median for Receivables - Net is $253.2 million (2023), against an average of $251.5 million.
  • The largest YoY upside for Receivables - Net was 28.29% in 2021 against a maximum downside of 8.96% in 2021.
  • A 5-year view of Receivables - Net shows it stood at $231.8 million in 2021, then rose by 13.65% to $263.5 million in 2022, then decreased by 1.57% to $259.3 million in 2023, then increased by 5.03% to $272.4 million in 2024, then rose by 2.38% to $278.8 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Receivables - Net are $278.8 million (Q4 2025), $262.2 million (Q3 2025), and $284.5 million (Q2 2025).